MCRB - Seres Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
MCRB price evolution
MCRB
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $81.11 | $119.61 | $136.15 | |
| Short term investments | ||||
| Net receivables | $18.6 | $7.42 | $8.67 | |
| Inventory | $53 | $41.97 | $29.65 | |
| Total current assets | $72.93 | $149.26 | $165.18 | $175.41 |
| Long term investments | $1.4 | $1.4 | ||
| Property, plant & equipment | $95.48 | $121.08 | $124.78 | $132.25 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $172.47 | $176.08 | $183.19 | |
| Total investments | $1.4 | $1.4 | ||
| Total assets | $178.74 | $321.73 | $341.26 | $358.6 |
| Current liabilities | ||||
| Accounts payable | $8.25 | $4.81 | $5.22 | $3.64 |
| Deferred revenue | $103.29 | $103.47 | $103.09 | |
| Short long term debt | $9.2 | $8.83 | $6.68 | |
| Total current liabilities | $64.83 | $108.28 | $98.48 | $98.66 |
| Long term debt | $203.43 | $205.35 | $207.26 | |
| Total noncurrent liabilities | $300.52 | $302.52 | $304.8 | |
| Total debt | $212.63 | $214.18 | $213.94 | |
| Total liabilities | $154.82 | $408.81 | $401 | $403.46 |
| Shareholders' equity | ||||
| Retained earnings | -$962.46 | -$1051.24 | -$1018.37 | -$978.24 |
| Other shareholder equity | ||||
| Total shareholder equity | -$87.07 | -$59.74 | -$44.86 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $136.15 | $171.22 | $188 | $116.05 |
| Short term investments | $18.31 | $110.7 | $137.57 | |
| Net receivables | $8.67 | $9.39 | ||
| Inventory | $29.65 | |||
| Total current assets | $175.41 | $194.76 | $303.63 | $268.78 |
| Long term investments | $1.4 | $1.4 | $1.9 | $51.23 |
| Property, plant & equipment | $132.25 | $133.97 | $36.15 | $22.94 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $183.19 | $154.02 | $51.23 | $74.16 |
| Total investments | $1.4 | $19.71 | $112.6 | $188.79 |
| Total assets | $358.6 | $348.78 | $354.86 | $342.94 |
| Current liabilities | ||||
| Accounts payable | $3.64 | $17.44 | $13.73 | $4.02 |
| Deferred revenue | $103.09 | $96.69 | $103.82 | $108.17 |
| Short long term debt | $6.68 | $4.06 | $6.61 | $5.57 |
| Total current liabilities | $98.66 | $85.6 | $82.26 | $46.41 |
| Long term debt | $207.26 | $50.59 | $42.6 | $35.2 |
| Total noncurrent liabilities | $304.8 | $252.41 | $141.09 | $121.78 |
| Total debt | $213.94 | $162.59 | $49.21 | $40.77 |
| Total liabilities | $403.46 | $338 | $223.35 | $168.19 |
| Shareholders' equity | ||||
| Retained earnings | -$978.24 | -$864.51 | -$614.35 | -$548.78 |
| Other shareholder equity | -$0.01 | -$0.06 | -$0.05 | |
| Total shareholder equity | -$44.86 | $10.78 | $131.51 | $174.75 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.06 | |||
| Cost of revenue | ||||
| Gross Profit | $0.06 | |||
| Operating activities | ||||
| Research & development | $17.88 | $21.7 | $26.85 | |
| Selling, general & administrative | $16.06 | $15.47 | $17.23 | |
| Total operating expenses | $31.34 | $39.59 | $39.59 | |
| Operating income | -$31.34 | -$39.59 | -$39.53 | |
| Income from continuing operations | ||||
| EBIT | -$29.42 | -$35.47 | -$37.22 | |
| Income tax expense | ||||
| Interest expense | $3.45 | $4.66 | $4.03 | |
| Net income | ||||
| Net income | -$32.87 | -$40.13 | -$41.25 | |
| Income (for common shares) | -$32.87 | -$40.13 | -$41.25 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $126.33 | $7.13 | $144.93 | $33.22 |
| Cost of revenue | ||||
| Gross Profit | $126.33 | $7.13 | $144.93 | $33.22 |
| Operating activities | ||||
| Research & development | $145.86 | $172.92 | $141.89 | $90.57 |
| Selling, general & administrative | $87.74 | $79.69 | $69.26 | $30.77 |
| Total operating expenses | $234.31 | $253.62 | $209.42 | $121.34 |
| Operating income | -$107.98 | -$246.49 | -$64.49 | -$88.13 |
| Income from continuing operations | ||||
| EBIT | -$100.55 | -$244.14 | -$62.67 | -$86.2 |
| Income tax expense | ||||
| Interest expense | $13.18 | $6.02 | $2.91 | $2.92 |
| Net income | ||||
| Net income | -$113.72 | -$250.16 | -$65.58 | -$89.13 |
| Income (for common shares) | -$113.72 | -$250.16 | -$65.58 | -$89.13 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$32.87 | -$40.13 | -$41.25 | |
| Operating activities | ||||
| Depreciation | $3.81 | $3.95 | $4.05 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.53 | $6.49 | $5.09 | |
| Total cash flows from operations | -$39.81 | -$35.24 | -$47.5 | |
| Investing activities | ||||
| Capital expenditures | -$0.1 | -$0.06 | -$0.88 | |
| Investments | $1.4 | |||
| Total cash flows from investing | $142.38 | $1.3 | -$0.06 | -$0.88 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $18.76 | $6.43 | ||
| Net borrowings | ||||
| Total cash flows from financing | -$92.11 | $18.76 | $6.43 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$59.45 | -$38.51 | -$16.54 | -$41.95 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$113.72 | -$250.16 | -$65.58 | -$89.13 |
| Operating activities | ||||
| Depreciation | $15.11 | $11.85 | $9.22 | $8.89 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $34.1 | $25.48 | $20.22 | $8.82 |
| Total cash flows from operations | -$117.35 | -$228.82 | $6.69 | -$93.61 |
| Investing activities | ||||
| Capital expenditures | -$7.97 | -$9.82 | -$9.57 | -$0.59 |
| Investments | $18.56 | $92.25 | $73.65 | -$158.3 |
| Total cash flows from investing | $10.58 | $82.43 | $64.09 | -$158.89 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $21.19 | $103.9 | $2.13 | $303.42 |
| Net borrowings | $50.52 | $25.7 | -$0.95 | |
| Total cash flows from financing | $71.7 | $129.6 | $1.18 | $303.42 |
| Effect of exchange rate | $0 | -$0 | -$0 | |
| Change in cash and equivalents | -$35.07 | -$16.79 | $71.95 | $50.92 |
News
Fundamentals
| Market cap | $125.10M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 170.20M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | -8.99 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.12 |
| Quick ratio | N/A |